Funding Opportunity RFA-OH-22-003 from the NIH Guide for Grants and Contracts. The purpose of this program is to support NIOSH TPGs, to address the burden of OSH in the United States by providing state-of-the-art training for the next generation of leaders in OSH practice and research.

Funding Opportunity RFA-DK-21-029 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2021 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org (http://www.diabetescenters.org).

Funding Opportunity PAR-22-048 from the NIH Guide for Grants and Contracts. There is consensus that environmental toxicants are a risk factor for AD/ADRD, but causality has been largely elusive. While human studies demonstrating an association of AD/ADRD with toxicant exposures are relatively abundant, there is a clear unmet need for more mechanistic research to support or refute the clinical relevance and the biological plausibility of an impact on disease initiation, progression, or modification. This is especially important for understanding the potentially modifiable causes of racial and socioeconomic inequities. The RFA will encourage neuroscientists to conduct mechanistic AD/ADRD research on the actions of neurotoxicants on the nervous system. The scope of research includes but is not limited to in silico modeling, in vitro assay development to correlate chemical exposure to AD/ADRD biology, and in vivo studies on the modification of known AD/ADRD targets by neurotoxicants of concern, and conversely, whether known targets for these neurotoxins play a role in the etiology of AD/ADRD. The development and validation of neuropathological, neurophysiological, and neurobehavioral animal models that simulate potential toxicant exposures in humans would be one goal, and when possible, these studies will include comparisons of exposures across the lifespan.

Notice NOT-MH-22-010 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-22-021 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications from institutions/organizations interested in participating with the NICHD in an ongoing multicenter clinical program, the Pelvic Floor Disorders Network, which is designed to study clinical and health aspects of pelvic floor disorders in adult women.

Funding Opportunity RFA-HD-22-022 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications from institutions/organizations to participate with the NICHD as the Data Coordinating Center in an ongoing multicenter clinical program, the Pelvic Floor Disorders Network, designed to study clinical and health aspects of pelvic floor disorders in women.

Notice NOT-OD-22-002 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-026 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-003 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-038 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-941. The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates)are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs.

Funding Opportunity PAR-22-039 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-942. The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not withinthe scope of this announcement.

£37,865-£45,359 per annum + benefits: Wellcome Sanger Institute: We are looking for an experienced bioinformatician to be responsible for the informatics and data infrastructure, and perform research analyses, fo... Cambridge, Cambridgeshire (GB)

Funding Opportunity PAR-21-341 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (epidemiologic, biomedical, behavioral, health care delivery or clinical).

Notice NOT-HD-21-044 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-001 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-004 from the NIH Guide for Grants and Contracts

Salary between £46,000-£52,000 per annum inclusive, subject to skills & experience.: The Francis Crick Institute: The Bioinformatics Training Developer will provide support to the bioinformatics training and development needs of research scientists. London (Central), London (Greater)

Funding Opportunity PAR-22-040 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows in the NHLBI Division of Intramural Research the opportunity to transition their research programs as new investigators to extramural institutions. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution.

Funding Opportunity PAR-22-034 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers still in training in the NHLBI Division of Intramural Research the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing to serve as lead investigator of a clinical trial or an ancillary study to an ongoing clinical trial, should apply to the companion FOA, PAR-22-040 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22- Clinical Trial Required).

Notice NOT-TR-22-002 from the NIH Guide for Grants and Contracts